This material is based upon work supported (or supported in part) by the Office of Research and Development Medical Research Service (or) Health Services R&D Service, Department of Veterans Affairs. This study was supported by NIMH grants R01 MH65571, R01 MH65588, R01 MH65562, R01 MH65707, R01 MH65554, R01 MH65578, and R01 MH65558.
Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: Data from the COGS study
Article first published online: 5 APR 2010
Journal compilation © 2010 Society for Psychophysiological Research. No claim to original US government works
Volume 47, Issue 5, pages 846–856, September 2010
How to Cite
Radant, A. D., Dobie, D. J., Calkins, M. E., Olincy, A., Braff, D. L., Cadenhead, K. S., Freedman, R., Green, M. F., Greenwood, T. A., Gur, R. E., Gur, R. C., Light, G. A., Meichle, S. P., Millard, S. P., Mintz, J., Nuechterlein, K. H., Schork, N. J., Seidman, L. J., Siever, L. J., Silverman, J. M., Stone, W. S., Swerdlow, N. R., Tsuang, M. T., Turetsky, B. I. and Tsuang, D. W. (2010), Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: Data from the COGS study. Psychophysiology, 47: 846–856. doi: 10.1111/j.1469-8986.2010.01004.x
- Issue published online: 2 AUG 2010
- Article first published online: 5 APR 2010
- (Received December 23, 2008; Accepted October 23, 2009)
The antisaccade task is a widely used technique to measure failure of inhibition, an important cause of cognitive and clinical abnormalities found in schizophrenia. Although antisaccade performance, which reflects the ability to inhibit prepotent responses, is a putative schizophrenia endophenotype, researchers have not consistently reported the expected differences between first-degree relatives and comparison groups. Schizophrenia participants (n=219) from the large Consortium on the Genetics of Schizophrenia (COGS) sample (n=1078) demonstrated significant deficits on an overlap version of the antisaccade task compared to their first-degree relatives (n=443) and community comparison subjects (CCS; n=416). Although mean antisaccade performance of first-degree relatives was intermediate between schizophrenia participants and CCS, a linear mixed-effects model adjusting for group, site, age, and gender found no significant performance differences between the first-degree relatives and CCS. However, admixture analyses showed that two components best explained the distributions in all three groups, suggesting two distinct doses of an etiological factor. Given the significant heritability of antisaccade performance, the effects of a genetic polymorphism is one possible explanation of our results.